Results 61 to 70 of about 334,470 (291)
Therapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report
medRxiv, 2021 Background Thrombosis may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.
E. Goligher +31 more
semanticscholar +1 more source
Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [PDF]
, 2003 Only very limited data are available concerning patient adherence to antithrombotic medication intended to prevent a recurrent stroke. Reduced adherence and compliance could significantly influence the effects of any stroke prevention strategies.
Busse, O. +4 more
core +1 more source
Clinical controversies in anticoagulation monitoring and antithrombin supplementation for ECMO
Critical Care, 2020 During extracorporeal membrane oxygenation (ECMO), a delicate balance is required to titrate systemic anticoagulation to prevent thrombotic complications within the circuit and prevent bleeding in the patient.
Meghan M. Chlebowski +4 more
semanticscholar +1 more source
Update on Extended Treatment for Venous Thromboembolism [PDF]
, 2018 The importance of assessing the probability of venous thromboembolism recurrence, a condition that includes deep vein thrombosis and pulmonary embolism, lies in the fact that it is the most important factor in deciding the duration of anticoagulant ...
Del Toro-Cervera, Jorge +7 more
core +2 more sources
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Thrombosis and Haemostasis, 2020 Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has been proposed as therapy to decrease mortality, often adjusted for illness severity.
H. Billett +11 more
semanticscholar +1 more source
Frontiers in Pharmacology, 2023 Background: The benefits and risks of starting anticoagulation therapy, such as direct oral anticoagulations (DOACs) or warfarin, in atrial fibrillation (AF) patients with a history of intracranial hemorrhage (ICH) remain controversial.
Qiang Zhou +6 more
doaj +1 more source
Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]
, 2018 It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P +5 more
core +1 more source
A retrospective comparative study of three data modelling techniques in anticoagulation therapy. [PDF]
, 2008 Three types of data modelling technique are applied retrospectively to individual patients’ anticoagulation therapy data to predict their future levels of anticoagulation.
Angelov, Plamen +2 more
core +1 more source
Secondary thrombosis prevention practice patterns in pediatrics: Results of an international survey
Research and Practice in Thrombosis and Haemostasis, 2022 Background Pediatric venous thromboembolism (VTE) rates continue to increase. Although most children present with transient provoking factors, some have persistent prothrombotic risks beyond the initial treatment period warranting secondary ...
Hope P. Wilson +4 more
doaj +1 more source
Hematology, 2001 Abstract Despite refinements and standardization in the use of anticoagulants, many problems remain for clinicians. Dr. Crowther describes appropriate starting and maintenance doses of warfarin, factors accounting for inter- and intra-observer variability and importantly, the management of the over-anticoagulated patients and bleeding ...
J A, Ginsberg +3 more
openaire +2 more sources